Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity ...

In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...

Kentucky, Alaska and Alabama are the three states where weight loss drugs are most used, and Hawaii, Arizona and Colorado sit ...

AstraZeneca PLC shed GBP15 billion of market capitalization on Tuesday, after investors were underwhelmed by early data from a trial of a weight-loss pill. The company (UK:AZN) said its lead product ...

Zealand is po­si­tion­ing the drug as a po­ten­tial stand­alone re­place­ment for GLP-1s or as the first med­i­cine that ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...

Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

Novo Nordisk ( NVO, Financials) entered an exclusive agreement with Ascendis Pharma ( ASND, Financials) to license Ascendis's TransCon technology platform for developing novel treatments targeting ...

With Novo Nordisk’s patent on semaglutide set to expire in India, Dr Reddy’s is among the forerunners trying to bring the ...

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...

Medications like Ozempic and Wegovy, which are used to treat type 2 diabetes and boost weight loss, may also help reduce knee ...

While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...